Inovio Pharmaceuticals (INO) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable
2. 02We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology
3. 03A small number of licensing partners and government contracts have accounted for a substantial portion of our revenue
4. 04We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain

Risks Related to Product Development, Manufacturing and Regulatory Approval

1. 05Pursuing accelerated approval for INO-3107 or any of our other product candidates may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval
2. 06Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States
3. 07Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results
4. 08Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues
5. 09None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products
6. 10market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products
7. 11business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop
8. 12We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our proprietary device and DNA medicine candidates
9. 13If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted
10. 14being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints
11. 15A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval

Risks Related to Reliance on Third Parties

1. 16If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer
2. 17We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates
3. 18We enter into various contracts in the normal course of our business in which we agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations

Risks Related to Commercialization of Our DNA Medicine Candidates

1. 19We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues
2. 20If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited
3. 21We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success

Risks Related to Employee and Operational Matters

1. 22We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation
2. 23We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates
3. 24Our business could be adversely affected by the effects of health epidemics
4. 25We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to develop and commercialize our DNA medicines
5. 26We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases
6. 27We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products
7. 28Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business
8. 29systems and technologies. Furthermore, we may discover security issues that were not found during diligence of such acquired or integrated entities and it may be difficult to integrate such entities into our programs
9. 30We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability
10. 31Healthcare reform measures could hinder or prevent our products' commercial success
11. 32If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected
12. 33The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws
13. 34Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business
14. 35Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
15. 36Employee litigation and unfavorable publicity could negatively affect our future business

Risks Related to Our Intellectual Property

1. 37It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection
2. 38Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges
3. 39If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business
4. 40We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business

Risks Related to an Investment in Our Common Stock

1. 41An active trading market for our common stock may not be sustained
2. 42The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value
3. 43We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively
4. 44Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock
5. 45We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future
6. 46Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
7. 47Our quarterly operating results may fluctuate significantly
8. 48Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions
9. 49Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, could adversely impact our business, financial condition and results of operations
10. 50If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
11. 51The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders
12. 52We incur significant costs and demands upon management as a result of being a public company
13. 53Changes in tax laws could adversely affect our business and financial condition
14. 54The increasing use of social media platforms presents new risks and challenges
15. 55Our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security